Skip Nav Destination
![]()
You do not currently have access to this content.
With Vorasidenib, Glioma Treatment Continues Evolving Available to Purchase
September 4, 2024
Abstract: The FDA’s approval of vorasidenib for IDH-mutant low-grade gliomas offers the first systemic therapy for these patients, potentially delaying more aggressive treatments. This targeted approach could balance the need for tumor control with quality-of-life considerations.
RSS Feeds